美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Western Asset Investment Grade D

16.36

-0.0700-0.43%

盘后：16.360.00000.00%16:04 EDT

成交量：2.41万

成交额：39.41万

市值：9,805.61万

市盈率：-4.76

高：16.43

开：16.40

低：16.25

收：16.43

数据加载中...

总览公司新闻公告

巨头加码，三抗成为“新风口”

19.25亿，艾伯维引进CD3/BCMA/CD38管线

静安：品牌之夜孵化机遇共绘时尚产业新未来

看看新闻KNEWS

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/IGI/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IGI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IGI\",,,,,undefined,":{"symbol":"IGI","market":"US","secType":"STK","nameCN":"Western Asset Investment Grade D","latestPrice":16.36,"timestamp":1753732800000,"preClose":16.43,"halted":0,"volume":24139,"hourTrading":{"tag":"盘后","latestPrice":16.36,"preClose":16.36,"latestTime":"16:04 EDT","volume":17,"amount":277.82,"timestamp":1753733050868},"delay":0,"floatShares":0,"shares":5993650,"eps":-3.44,"marketStatus":"未开盘","change":-0.07,"latestTime":"07-28 16:00:00 EDT","open":16.4,"high":16.43,"low":16.25,"amount":394065.3022,"amplitude":0.010956,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.44,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753776000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":16.43,"dividendRate":0.051956,"postHourTrading":{"tag":"盘后","latestPrice":16.36,"preClose":16.36,"latestTime":"16:04 EDT","volume":17,"amount":277.82,"timestamp":1753733050868},"volumeRatio":1.325037},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IGI\",,,,,undefined,":{"symbol":"IGI","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.325037,"shares":5993650,"dividePrice":0.85,"high":16.43,"amplitude":0.010956,"preClose":16.43,"low":16.25,"week52Low":15.7,"pbRate":"--","week52High":18.3,"institutionHeld":0,"latestPrice":16.36,"eps":-3.44,"divideRate":0.051956,"volume":24139,"delay":0,"ttmEps":-3.44,"open":16.4,"prevYearClose":16.31,"prevWeekClose":16.43,"prevMonthClose":16.58,"prevQuarterClose":16.58,"fiveDayClose":16.475,"twentyDayClose":16.58,"sixtyDayClose":16.31},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IGI\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552107687","title":"巨头加码，三抗成为“新风口”","url":"https://stock-news.laohu8.com/highlight/detail?id=2552107687","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552107687?lang=zh_cn&edition=fundamental","pubTime":"2025-07-17 16:03","pubTimestamp":1752739384,"startTime":"0","endTime":"0","summary":"ISB 2001在组合中加入CD38，增强对BCMA低表达肿瘤细胞的结合能力，并通过下调抗原表达来阻止癌症产生耐药性，有望成为新一代治疗多发性骨髓瘤的药物。02三抗正在成为新风口单克隆抗体药物因其特异性强、靶向性高和毒副作用小等特点，已在肿瘤、自身性免疫疾病等领域广泛应用。目前，全球已有多款双特异性抗体药物获批上市，适应证主要集中在肿瘤领域。在国内药企中，三特异性抗体同样受到追崇。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717161118a6af3e8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717161118a6af3e8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IGI","IE00B7SZL793.SGD","BK4077","CRS","BK4006","BK4161","MRK","IE00B19Z4B17.USD","IE00B66KJ199.SGD","CR","AZN","JNJ","LU2065731478.USD","ORR","PFE","IE0031619046.USD","SLE"],"gpt_icon":0},{"id":"2551912315","title":"19.25亿，艾伯维引进CD3/BCMA/CD38管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2551912315","media":"药渡","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551912315?lang=zh_cn&edition=fundamental","pubTime":"2025-07-13 07:30","pubTimestamp":1752363052,"startTime":"0","endTime":"0","summary":"ISB 2001 是同类首创的三特异性 T 细胞接合剂，靶向骨髓瘤细胞上的 BCMA 和 CD38 以及 T 细胞上的 CD3，目前正处于复发/难治性多发性骨髓瘤的 I 期临床研究。在25 名对抗 CD38 疗法有耐药性的患者中，ORR 为 72%，CR/sCR 率为 24%。在15 名接受过 BCMA 靶向治疗的患者中，ORR 为 73%，CR/sCR 率为 27%。CD3/BCMA/CD38三抗业界做的人不多，其实2020年有文章初步显示，做三抗具有一定可行性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713073357a447180c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250713073357a447180c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0820561909.HKD","CRS","LU0689472784.USD","LU1267930490.SGD","LU0861579265.USD","BK4568","IE00B2B36J28.USD","ABBV","LU0965508806.USD","LU1032466523.USD","LU2430703251.USD","LU0211327993.USD","BK4592","LU1934455277.USD","LU2505996681.GBP","LU1914381329.SGD","LU1674673691.USD","IE00B4R5TH58.HKD","RR","BK4566","LU0792757196.USD","IGI","LU1894683264.USD","IE00BJJMRZ35.SGD","BK4007","IE00BDGV0183.EUR","LU0456855351.SGD","IE00B3PB1722.GBP","LU0708994859.HKD","LU2602419157.SGD","IE00B7SZL793.SGD","LU1496350502.SGD","LU1093756325.SGD","LU1244550221.USD","IE00BVYPNW00.USD","LU1267930573.SGD","LU0114720955.EUR","LU1066051225.USD","LU0256863811.USD","LU2089284900.SGD","LU0889566641.SGD","LU2087621335.USD","LU2237443465.HKD","LU0965509283.SGD","LU0320765646.SGD","SG9999015945.SGD","IE00B66KJ199.SGD","LU2347655156.SGD","JNJ","IE0004445239.USD"],"gpt_icon":0},{"id":"2542538509","title":"静安：品牌之夜孵化机遇 共绘时尚产业新未来","url":"https://stock-news.laohu8.com/highlight/detail?id=2542538509","media":"看看新闻KNEWS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542538509?lang=zh_cn&edition=fundamental","pubTime":"2025-06-11 21:41","pubTimestamp":1749649260,"startTime":"0","endTime":"0","summary":"在“2025首届中国时尚产业盛典”举办之际，作为上海时尚文化的核心地标，6月11日晚，静安在上海张园举行“静安品牌之夜”。这一系列重量级项目的落地，将有力促进静安时尚产业从设计研发、智能制造到品牌营销的全链条升级，标志着静安时尚产业生态体系迈入全球化、高端化发展的新阶段。这些地标将汇聚国际顶级时尚资源，成为静安乃至上海时尚产业的新名片，助力中国时尚走向世界舞台。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-06-11/doc-ineztmqw2198454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IGI"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IGI\",params:#limit:5,,,undefined,":[{"date":"2025-08-22","symbol":"IGI","amount":0.071,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-22","defaultRemindTime":1755869400000,"name":"Western Asset Investment Grade D","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-02","payableDate":"2025-08-22","currency":"USD","dateTimestamp":1755835200000,"payDate":"2025-09-02"},{"date":"2025-07-24","symbol":"IGI","amount":0.071,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-24","defaultRemindTime":1753363800000,"name":"Western Asset Investment Grade D","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-01","payableDate":"2025-07-24","currency":"USD","dateTimestamp":1753329600000,"payDate":"2025-08-01"},{"date":"2025-06-23","symbol":"IGI","amount":0.071,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Western Asset Investment Grade D","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-07-01"},{"date":"2025-05-22","symbol":"IGI","amount":0.071,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-22","defaultRemindTime":1747920600000,"name":"Western Asset Investment Grade D","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-02","payableDate":"2025-05-22","currency":"USD","dateTimestamp":1747886400000,"payDate":"2025-06-02"},{"date":"2025-04-23","symbol":"IGI","amount":0.071,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-23","defaultRemindTime":1745415000000,"name":"Western Asset Investment Grade D","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-01","payableDate":"2025-04-23","currency":"USD","dateTimestamp":1745380800000,"payDate":"2025-05-01"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IGI\",market:\"US\",,,undefined,":[{"executeDate":"2015-08-19","recordDate":"2015-08-21","paymentDate":"2015-08-28","value":0.1,"currency":"USD"},{"executeDate":"2015-09-16","recordDate":"2015-09-18","paymentDate":"2015-09-25","value":0.1,"currency":"USD"},{"executeDate":"2015-10-21","recordDate":"2015-10-23","paymentDate":"2015-10-30","value":0.1,"currency":"USD"},{"executeDate":"2015-11-18","recordDate":"2015-11-20","paymentDate":"2015-11-27","value":0.1,"currency":"USD"},{"executeDate":"2015-12-16","recordDate":"2015-12-18","paymentDate":"2015-12-24","value":0.1,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IGI\",market:\"US\",delay:false,,,undefined,":{}}}